The Beauty Health Company
SKINNASDAQConsumer Defensive● Active
$0.64
+$0.03(+5.58%)
Market Cap$83138400
P/E Ratio—
52W High$2.69
52W Low$0.551
The Beauty Health Company (SKIN) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
SKIN · earnings · updated Jun 8, 2026
Latest Earnings
Q2 FY2026Report Date: May 7, 2026EPS Actual
-$0.05
Est. -$0.09 · +44.4%
Revenue
$0.06B
Est. $0.07B · -2.1%
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 7, 2026
After Market Close
▲ Beat EPS▼ Miss Revenue✓ 2-Quarter EPS Beat Streak
SKIN reports quarterly as a NASDAQ-listed Household & Personal Products company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
85
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
—
Rev. $0.58B
Days Away85
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.—
Rev. Est.$0.58B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 6, 2026 | -$0.03 | — | — | — | $0.07B | — |
| ▲ Q2 FY2026 | May 7, 2026 | -$0.09 | -$0.05 | +44.4% | $0.06B | $0.07B | -2.1% |
| ▲ Q1 FY2026 | Mar 12, 2026 | -$0.07 | -$0.06 | +14.3% | $0.08B | $0.08B | +5.4% |
| ▼ Q4 FY2025 | Nov 6, 2025 | -$0.08 | -$0.09 | -12.5% | $0.07B | $0.08B | -9.5% |
| ▲ Q3 FY2025 | Aug 7, 2025 | -$0.06 | $0.03 | +150.0% | $0.08B | $0.07B | +14.4% |
| ▲ Q2 FY2025 | May 8, 2025 | -$0.13 | -$0.08 | +38.5% | $0.07B | $0.06B | +10.3% |
| ▲ Q1 FY2025 | Mar 12, 2025 | -$0.10 | -$0.08 | +20.0% | $0.08B | $0.08B | +7.8% |
| ▼ Q4 FY2024 | Nov 12, 2024 | -$0.12 | -$0.15 | -25.0% | $0.08B | $0.08B | +1.3% |
Q3 FY2026
Aug 6, 2026
EPS Actual
—
EPS Est.
-$0.03
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 7, 2026Beat
EPS Actual
-$0.05
EPS Est.
-$0.09
EPS Surpr.
+44.4%
Revenue
$0.06B
Q1 FY2026
Mar 12, 2026Beat
EPS Actual
-$0.06
EPS Est.
-$0.07
EPS Surpr.
+14.3%
Revenue
$0.08B
Q4 FY2025
Nov 6, 2025Miss
EPS Actual
-$0.09
EPS Est.
-$0.08
EPS Surpr.
-12.5%
Revenue
$0.07B
Q3 FY2025
Aug 7, 2025Beat
EPS Actual
$0.03
EPS Est.
-$0.06
EPS Surpr.
+150.0%
Revenue
$0.08B
Q2 FY2025
May 8, 2025Beat
EPS Actual
-$0.08
EPS Est.
-$0.13
EPS Surpr.
+38.5%
Revenue
$0.07B
Q1 FY2025
Mar 12, 2025Beat
EPS Actual
-$0.08
EPS Est.
-$0.10
EPS Surpr.
+20.0%
Revenue
$0.08B
Q4 FY2024
Nov 12, 2024Miss
EPS Actual
-$0.15
EPS Est.
-$0.12
EPS Surpr.
-25.0%
Revenue
$0.08B
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $-0.02 | $-0.02 | $-0.02 | 1 |
| Q3 FY2027 | $-0.04 | $-0.04 | $-0.04 | 1 |
| Q2 FY2027 | $-0.02 | $-0.02 | $-0.02 | 1 |
| Q1 FY2027 | $-0.06 | $-0.05 | $-0.05 | 1 |
| Q4 FY2026 | $-0.01 | $-0.01 | $-0.01 | 1 |
| Q3 FY2026 | $-0.08 | $-0.05 | $0.01 | 5 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $0.1B | $0.1B | $0.1B | 3 |
| Q3 FY2027 | $0.1B | $0.1B | $0.1B | 3 |
| Q2 FY2027 | $0.1B | $0.1B | $0.1B | 3 |
| Q1 FY2027 | $0.1B | $0.1B | $0.1B | 3 |
| Q4 FY2026 | $0.1B | $0.1B | $0.1B | 5 |
| Q3 FY2026 | $0.1B | $0.1B | $0.1B | 6 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▲ Q2 FY2026 | May 7, 2026 | +44.4% | $0.93 | $0.91 | -2.43% |
| ▲ Q1 FY2026 | Mar 12, 2026 | +14.3% | $1.13 | $1.06 | -6.19% |
| ▼ Q4 FY2025 | Nov 6, 2025 | -12.5% | $1.47 | $1.29 | -12.24% |
| ▲ Q3 FY2025 | Aug 7, 2025 | +150.0% | $1.59 | $1.59 | +0.00% |
| ▲ Q2 FY2025 | May 8, 2025 | +38.5% | $1.42 | $1.24 | -12.68% |
| ▲ Q1 FY2025 | Mar 12, 2025 | +20.0% | $1.36 | $1.42 | +4.41% |
| ▼ Q4 FY2024 | Nov 12, 2024 | -25.0% | $1.76 | $1.70 | -3.41% |
| ▼ Q3 FY2024 | Aug 8, 2024 | -100.0% | $1.25 | $1.29 | +3.20% |
Q2 FY2026-2.43%
Report Date
May 7, 2026
EPS Beat/Miss
+44.4%
Price Before
$0.93
Price After
$0.91
Q1 FY2026-6.19%
Report Date
Mar 12, 2026
EPS Beat/Miss
+14.3%
Price Before
$1.13
Price After
$1.06
Q4 FY2025-12.24%
Report Date
Nov 6, 2025
EPS Beat/Miss
-12.5%
Price Before
$1.47
Price After
$1.29
Q3 FY2025+0.00%
Report Date
Aug 7, 2025
EPS Beat/Miss
+150.0%
Price Before
$1.59
Price After
$1.59
Q2 FY2025-12.68%
Report Date
May 8, 2025
EPS Beat/Miss
+38.5%
Price Before
$1.42
Price After
$1.24
Q1 FY2025+4.41%
Report Date
Mar 12, 2025
EPS Beat/Miss
+20.0%
Price Before
$1.36
Price After
$1.42
Q4 FY2024-3.41%
Report Date
Nov 12, 2024
EPS Beat/Miss
-25.0%
Price Before
$1.76
Price After
$1.70
Q3 FY2024+3.20%
Report Date
Aug 8, 2024
EPS Beat/Miss
-100.0%
Price Before
$1.25
Price After
$1.29
Avg Beat Reaction-3.38%
Avg Miss Reaction-4.15%
Beat Rate5 / 8 quarters
Largest Move-12.68% (Q2 FY2025)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: SKIN ends December
The Beauty Health Company (SKIN) most recently reported earnings on May 7, 2026 for Q2 FY2026, posting EPS of $-0.05 — beating the analyst consensus of $-0.09 by +44.4%. SKIN has beaten EPS estimates for 2 consecutive quarters. The next SKIN earnings date is expected around September 1, 2026.
Each quarter, investors track SKIN earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. SKIN revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
SKIN's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
SKIN earnings · 5 questionsThe Beauty Health Company's next earnings report is expected around September 1, 2026. SKIN typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; SKIN historically reports after market close (AMC).
SKIN earnings datewhen is SKIN earningsSKIN next earnings datewhen does SKIN report earningsSKIN earnings calendar
▸ Source: FMP · The Beauty Health Company SEC filings · US GAAP · The Beauty Health Company SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026